Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 ± anlotinib in recurrent or metastatic endometrial cancer
CTR20213383Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart, anlotinib in endometrial cancer (EC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2022; status: completed.
02
Drugs
benmelstobartanlotinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20213383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213383.